Minerva Neurosciences | NERV - Pre Tax Profit


Minerva Neurosciences reported $22.51M in Pre-Tax Profit for its fiscal quarter ending in September of 2024.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Adma Biologics USD 57.13M 4.47M Mar/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Alterity Therapeutics Limited AUD -6.26M 1.52M Dec/2025
AstraZeneca USD 4.81B 894M Jun/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Cipla INR 10.82B 3.33B Jun/2026
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD -7.66M 64.51M Mar/2026
CSL USD 2.61B 1.21B Dec/2025
Eli Lilly USD 8.85B 583.8M Mar/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Grifols EUR 257.85M 190.87M Dec/2024
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
J&J USD 7.67B 988M Sep/2026
Merck USD -3.53B 6.95B Mar/2026
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD -653M 5.84B Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sanofi EUR 837M 1.17B Jun/2026
Takeda JPY 162.72B 215.2B Jun/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024